This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 Mar;21(3):326-327.

doi: 10.1016/S1470-2045(20)30009-7. Epub 2020 Jan 27.

TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?

Cathy Eng¹

Affiliations

PMID: 31999945
DOI: 10.1016/S1470-2045(20)30009-7

Comment

TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?

Cathy Eng. Lancet Oncol. 2020 Mar.

. 2020 Mar;21(3):326-327.

doi: 10.1016/S1470-2045(20)30009-7. Epub 2020 Jan 27.

Author

Cathy Eng¹

Affiliation

¹ Vanderbilt-Ingram Cancer Center, Nashville 37232, TN, USA. Electronic address: cathy.eng@vumc.org.

PMID: 31999945
DOI: 10.1016/S1470-2045(20)30009-7

No abstract available

PubMed Disclaimer

Comment on

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Pfeiffer P, Yilmaz M, Möller S, Zitnjak D, Krogh M, Petersen LN, Poulsen LØ, Winther SB, Thomsen KG, Qvortrup C. Pfeiffer P, et al. Lancet Oncol. 2020 Mar;21(3):412-420. doi: 10.1016/S1470-2045(19)30827-7. Epub 2020 Jan 27. Lancet Oncol. 2020. PMID: 31999946 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science